drugset / Trial / NCT05655598
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: * Patients with advanced breast cancer that has become worse after taking palbociclib alone * Patients with cancers that have an abnormality in a gene called the "retinoblastoma gene".
Timeline
- Start
- 2023-09-12
- Primary completion
- 2024-08-05
- Completion
- 2024-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | TAS-116 | Small molecule | 40 mg | — |
| Subject | TAS-116 | Small molecule | 80 mg | — |
| Subject | TAS-116 | Small molecule | 120 mg | — |